Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Neoadjuvant Radioimmunotherapy Demonstrates Feasibility in Locally Advanced Urothelial Carcinoma

October 7th 2022

Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.

Sonpavde Reviews Urothelial Carcinoma Treatment Highlights from ESMO 2022

October 6th 2022

Guru P. Sonpavde, MD, provides commentary on several studies in urothelial carcinoma and how data presented at ESMO may affect clinical practice.

Dr. Desai on Immune Checkpoint Inhibitors with Chemoradiation in Urothelial Cancer

October 5th 2022

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Pembrolizumab Improves Outcomes Regardless of Response to Prior Chemotherapy in Advanced Urothelial Cancer

October 5th 2022

Response to pembrolizumab monotherapy was observed regardless of prior response to chemotherapy in patients with advanced urothelial cancer.

Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma

October 5th 2022

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

Incidence and Risk Factors for Urothelial Carcinoma

October 5th 2022

Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.

Dr. Zhang on Multidisciplinary Approaches in Urothelial Cancer

September 30th 2022

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial Carcinoma

September 30th 2022

The combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelial carcinoma.

Dr. Ornstein on Enfortumab Vedotin in Advanced Urothelial Carcinoma

September 29th 2022

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

September 28th 2022

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Dr. Barata on the Evolving Treatment Landscape in Urothelial Cancer

September 26th 2022

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Dr. Aragon-Ching on the Evolving Standard of Care with JAVELIN Bladder 100 in Urothelial Carcinoma

September 23rd 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Dr. Aragon-Ching on the Implications of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

September 21st 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

EphrinB2 Emerges as Targetable Option in Urothelial Carcinoma

September 20th 2022

Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

Enfortumab Vedotin Plus Pembrolizumab Produces Encouraging Responses in Metastatic Urothelial Cancer

September 12th 2022

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

POU2F2 May Be Predictive of Survival Benefit With Maintenance Avelumab in Urothelial Carcinoma

September 11th 2022

The absence of POU2F2, may be predictive of response to maintenance avelumab in patients with advanced or metastatic urothelial carcinoma, according to findings from an analysis peripheral blood samples taken in the JAVELIN Bladder 100 trial.

EphrinB2 Inhibition Plus Pembrolizumab Elicits Promising Activity in Progressive Metastatic Urothelial Carcinoma

August 30th 2022

Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

Dr. Barata on the Role of Maintenance Avelumab in Advanced Urothelial Cancer

August 29th 2022

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

Dr. Desai on the Ideal Patient for Bladder Preservation in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Dr. Desai on the Evolving Standard of Care in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.